Elsevier

Thrombosis Research

Volume 173, January 2019, Pages 77-78
Thrombosis Research

Letter to the Editors-in-Chief
Apixaban and rivaroxaban in patients with cerebral venous thrombosis

https://doi.org/10.1016/j.thromres.2018.11.018Get rights and content

Section snippets

Conflict of interest statement

The authors declare that they have no conflict of interest.

Funding

Department of Hematology and Oncology at Cleveland Clinic.

Author contributions

FC, HD contributed conception and design of study; FC, TK, OP, and MF collected the data; FC wrote the first draft of the manuscript. All authors contributed to manuscript revision and approved the submitted version.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

References (13)

  • M.G. Bousser et al.

    Cerebral venous thrombosis: an update

    Lancet Neurol.

    (2007)
  • S.K. Rao et al.

    Apixaban for the treatment of cerebral venous thrombosis: a case series

    J. Neurol. Sci.

    (2017)
  • S. Devasagayam et al.

    Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study

    Stroke

    (2016)
  • G. Saposnik et al.

    Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association

    Stroke

    (2011)
  • R. Bauersachs et al.

    Oral rivaroxaban for symptomatic venous thromboembolism

    N. Engl. J. Med.

    (2010)
  • G. Agnelli et al.

    Oral apixaban for the treatment of acute venous thromboembolism

    N. Engl. J. Med.

    (2013)
There are more references available in the full text version of this article.

Cited by (27)

  • Treatment of unusual thrombotic manifestations

    2020, Blood
    Citation Excerpt :

    Because the phase 3 RCTs conducted on direct oral anticoagulants (DOACs) did not include patients with unusual thrombotic manifestations,76 their safety and efficacy in this setting needs to be proven in dedicated clinical trials, and at present, their use should be discouraged. Limited data are available from 7 case series77-83 reporting on 44 patients with CVST treated with DOACs for a period varying from 3 to 19 months, with complete or partial recanalization achieved in ∼80% of cases without bleeding complications. Table 1 lists the ongoing clinical trials on treatment of CVST with DOACs.

View all citing articles on Scopus
View full text